| Record ID | marc_columbia/Columbia-extract-20221130-031.mrc:37846896:5377 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-031.mrc:37846896:5377?format=raw |
LEADER: 05377cam a2200757Ia 4500
001 15069413
005 20220604231719.0
006 m o d
007 cr cnu---unuuu
008 070302s2007 fluaf ob 001 0 eng d
010 $a 2006045588
035 $a(OCoLC)ocm85601717
035 $a(NNC)15069413
040 $aN$T$beng$epn$cN$T$dYDXCP$dOCLCQ$dCUSER$dIDEBK$dE7B$dOCLCQ$dTULIB$dOCLCQ$dCRCPR$dOCLCQ$dOCLCO$dMYG$dOCLCQ$dUAB$dCASUM$dOCLCO$dOCLCF$dOCLCQ$dUKMGB$dOCLCO$dWYU$dOCLCA$dVT2$dOCLCA$dOCLCQ$dCOO$dYDX$dTYFRS$dLEAUB$dUKAHL$dSTF$dK6U$dOCLCO
015 $aGBA659285$2bnb
016 7 $a018423994$2Uk
016 7 $z013504892$2Uk
019 $a228852564$a327018102$a647637827$a666976807$a779917822$a1004624042$a1009119112$a1058435346$a1066117282$a1086418340$a1162584252
020 $a9781420005400$q(electronic bk.)
020 $a1420005405$q(electronic bk.)
020 $z0849337747$q(hardcover)
020 $z9780849337741$q(hardcover)
020 $a9780429123733$q(e-book : PDF)
020 $a0429123736
024 7 $a10.1201/9781420005400$2doi
035 $a(OCoLC)85601717$z(OCoLC)228852564$z(OCoLC)327018102$z(OCoLC)647637827$z(OCoLC)666976807$z(OCoLC)779917822$z(OCoLC)1004624042$z(OCoLC)1009119112$z(OCoLC)1058435346$z(OCoLC)1066117282$z(OCoLC)1086418340$z(OCoLC)1162584252
037 $aTANDF_188592$bIngram Content Group
050 4 $aQP609.C93$bI54 2007eb
060 4 $a2007 A-467
060 4 $aQU 141$bI545 2007
072 7 $aMED$x062000$2bisacsh
072 7 $aHEA$x039030$2bisacsh
082 04 $a616.99/407$222
049 $aZCUA
245 00 $aInhibitors of cyclin-dependent kinases as anti-tumor agents /$cedited by Paul J. Smith, Eddy W. Yue.
260 $aBoca Raton :$bCRC/Taylor & Francis,$c©2007.
300 $a1 online resource (448 pages, 8 unnumbered pages of plates) :$billustrations (some color).
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aCRC enzyme inhibitors series
504 $aIncludes bibliographical references and index.
588 0 $aPrint version record.
505 0 $aPart Section 1: Integration of Cell Cycle Control Pathways and the Oppertunities for Targeting -- chapter 1 Cell Cycle Dynamics and the Challenges for CDK Targeting -- chapter 2 Functional Regulation of CIP/KIP CDK Inhibitors -- chapter 3 Mouse Models to Study the In Vivo Fuction of Cyclin-Dependent Kinases in Normal Homeostasis and Tumor Development -- chapter 4 Cyclin-Dependent Kinase Inhibitors and Vascular Disease -- part Section II: CDK Inhibitors: Targets and Their Evaluation -- chapter 5 Evaluation of CDK Inhibitor Selectivity: From Affinity Chromatography to Yeast Genetics -- chapter 6 Development of CDK Inhibitors as Anticancer Agents: From Rational Design to CDK4-Specific Inhibition -- chapter 7 Three-Dimensional Structures of Cyclin- Dependent Kinases and Their Inhibitor Complexes -- part Section III: CDK Inhibitors: Chemistry Focus -- chapter 8 Cyclin-Dependent Kinase Small Molecule Modulators for Cancer Therapy -- chapter 9 (R)-Roscovitine (CYC202, Seliciclib) -- chapter 10 Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors -- chapter 11 Discovery of BMS-387032, a Potent Cyclin-Dependent Kinase Inhibitor in Clinical Development -- chapter 12 Oxindole Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents -- chapter 13 Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors -- chapter 14 Development of Indolocarbazoles as Cyclin D1/CDK4 Inhibitors -- chapter 15 Pyrazoles as Efficient Adenine-Mimetic Heterocycles for the Discovery of CDK Inhibitors -- chapter 16 Pyrazolo[3,4-d]pyrimidin- 4-ones: Exploring the Structural Determinants of Potency and Selectivity in Cyclin-Dependent Kinase Inhibition -- part Section IV: Therapeutic Perspective -- chapter 17 Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status -- chapter 18 CDK Inhibitors as Anticancer Agents: Perspectives for the Future.
650 0 $aCyclin-dependent kinases$xInhibitors.
650 0 $aCyclin-dependent kinases$xInhibitors$xTherapeutic use$xTesting.
650 0 $aCancer$xChemotherapy.
650 12 $aCyclin-Dependent Kinases$xantagonists & inhibitors
650 12 $aCyclin-Dependent Kinases$xtherapeutic use
650 22 $aAntineoplastic Agents$xtherapeutic use
650 22 $aDrug Therapy$xmethods
650 6 $aKinases dépendantes des cyclines$xInhibiteurs.
650 6 $aKinases dépendantes des cyclines$xInhibiteurs$xEmploi en thérapeutique$xEssais.
650 6 $aCancer$xChimiothérapie.
650 7 $aMEDICAL$xOncology.$2bisacsh
650 7 $aHEALTH & FITNESS$xDiseases$xCancer.$2bisacsh
650 7 $aCancer$xChemotherapy.$2fast$0(OCoLC)fst00845327
650 7 $aFarmacoterapia del cáncer.$2lemb
655 0 $aElectronic books.
655 4 $aElectronic books.
700 1 $aSmith, Paul J.$q(Paul James),$d1953-
700 1 $aYue, Eddy W.
776 08 $iPrint version:$tInhibitors of cyclin-dependent kinases as anti-tumor agents.$dBoca Raton : CRC/Taylor & Francis, ©2007$z0849337747$z9780849337741$w(DLC) 2006045588$w(OCoLC)70046055
830 0 $aCRC enzyme inhibitors series.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15069413$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS